Trial Profile
Randomized controlled trial to evaluate the safety and efficacy of the medtronic AVE ABT-578 [zotarolimus] eluting driver coronary stent in de novo native coronary artery lesions.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
- Focus Registrational; Therapeutic Use
- Acronyms ENDEAVOR-II
- 08 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 May 2010 Planned end date changed from 1 May 2009 to 1 Jun 2010 as reported by ClinicalTrials.gov record.
- 15 Mar 2010 Five-year pooled analysis of ENDEAVOR programme including results from this trial presented at the 59th Annual Scientific Session of the American College of Cardiology (ACC), according to a Medtronic media release.